ArticlePloS one2016
Measuring IgA Anti-β2-Glycoprotein I and IgG/IgA Anti-Domain I Antibodies Adds Value to Current Serological Assays for the Antiphospholipid Syndrome.
Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 81 citations in OpenAlex.
- Anti-β2 glycoprotein domain 1 antibody as a diagnostic marker for antiphospholipid syndrome and a predictor of thrombosis: a systematic review and meta-analysis.Frontiers in immunology · 2025Pooled it
- Criteria and non-criteria anti-phospholipid antibodies in the different clinical forms of antiphospholipid syndrome.Frontiers in immunology · 2025Article
- Antiphospholipid antibody positivity in early systemic lupus erythematosus is associated with subsequent vascular events.Rheumatology (Oxford, England) · 2023Article
- Antiphospholipid antibodies in patients with calcific aortic valve stenosis.Rheumatology (Oxford, England) · 2023Article
- Thrombotic risk assessment in antiphospholipid syndrome: do noncriteria antibodies contribute?Turkish journal of medical sciences · 2023Article
- Antiphospholipid antibodies in autoimmune thyroid diseases.Journal of clinical laboratory analysis · 2022Article
- Research trends and frontiers on antiphospholipid syndrome: A 10-year bibliometric analysis (2012-2021).Frontiers in pharmacology · 2022Article
- The Role of Antiphospholipid Antibodies in COVID-19.Current rheumatology reports · 2021Review
- Understanding the Pathophysiology of Thrombotic APS through Animal Models.International journal of molecular sciences · 2021Review
- Specific domain V reduction of beta-2-glycoprotein I induces protein flexibility and alters pathogenic antibody binding.Scientific reports · 2021Article
- Current Promising Biomarkers and Methods in the Diagnostics of Antiphospholipid Syndrome: A Review.Biomedicines · 2021Review
- Pediatric Antiphospholipid Syndrome: from Pathogenesis to Clinical Management.Current rheumatology reports · 2021Review
- The Weight of IgA Anti-β2glycoprotein I in the Antiphospholipid Syndrome Pathogenesis: Closing the Gap of Seronegative Antiphospholipid Syndrome.International journal of molecular sciences · 2020Review
- Antiphospholipid syndrome.Translational research : the journal of laboratory and clinical medicine · 2020Review
- Seronegative antiphospholipid syndrome: refining the value of "non-criteria" antibodies for diagnosis and clinical management.Haematologica · 2020Review
- Immunoglobulin A Isotype of Antiphospholipid Antibodies Does Not Provide Added Value for the Diagnosis of Antiphospholipid Syndrome in a Chinese Population.Frontiers in immunology · 2020Article
- The role of beta-2-glycoprotein I in health and disease associating structure with function: More than just APS.Blood reviews · 2020Review
- Antiphospholipid antibody levels in early systemic lupus erythematosus: are they associated with subsequent mortality and vascular events?Rheumatology (Oxford, England) · 2020Article
- Improvements in diagnosis and risk assessment of primary and secondary antiphospholipid syndrome.Hematology. American Society of Hematology. Education Program · 2019Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 5 institutions in 3 countries.
Funding
Abstract
introductionCurrently available clinical assays to detect antiphospholipid antibodies (aPL) test for IgG and IgM antibodies to cardiolipin (aCL) and β2-glycoprotein I (aβ2GPI). It has been suggested that testing for IgA aPL and for antibodies to Domain I (DI), which carries the key antigenic epitopes of β2GPI, could add value to these current tests. We performed an observational, multicenter cohort study to evaluate the utility of IgG, IgM and IgA assays to each of CL, β2GPI and DI in APS.
methodsSerum from 230 patients with APS (n = 111), SLE but not APS (n = 119), and 200 healthy controls were tested for IgG, IgM and IgA aCL, aβ2GPI and aDI activity. Patients with APS were further classified into thrombotic or obstetric APS. Logistic regression and receiver operator characteristic analyses were employed to compare results from the nine different assays.
resultsAll assays displayed good specificity for APS; IgG aCL and IgG aβ2GPI assays however, had the highest sensitivity. Testing positive for IgA aβ2GPI resulted in a higher hazard ratio for APS compared to IgM aβ2GPI. Positive IgG, IgM or IgA aDI were all associated with APS, and in subjects positive for aCL and/or aβ2GPI, the presence of aDI raised the hazard ratio for APS by 3-5 fold. IgG aCL, aβ2GPI, aDI and IgA aDI were associated with thrombotic but not obstetric complications in patients with APS.
conclusionMeasuring IgG aDI and IgA aβ2GPI and aDI may be useful in the management of patients with APS, particularly thrombotic APS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.